Deciphera Pharmaceuticals, Inc. - Common Stock (DCPH)

DCPH stock results show that Deciphera Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.

U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc. (NASDAQ:AMZN) on Tuesday and Apple Inc.

ONO Pharmaceutical to acquire Deciphera Pharmaceuticals for $2.4B in cash. Deciphera brings specialized R&D in kinase drug discovery, commercial platforms, and a pipeline of cancer drugs including QINLOCK. Acquisition expected to close Q3 2024.

Mullen Automotive stock is climbing higher on Monday with heavy trading of MULN shares alongside it joining a new voucher program.

Shopify stock is on the rise Monday as shares of SHOP got an increased price target and an upgrade from Citi's analysts this morning.

Deciphera Pharmaceuticals stock is up on Monday after DCPH investors learned of a $2.4 billion acquisition deal with ONO Pharmaceutical.

The company is working on cancer treatments that block problematic kinases by targeting their switch-control pocket.

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced top-line results from the MOTION Phase 3 study of vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT) 

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.

Biotech stocks may offer some of the most explosive opportunities on the market. Here are three with major catalysts nearing.

All three biotech companies focus on oncology therapies.

The company's shares rose after the company reported second-quarter earnings.

Stifel upgraded Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) to Buy from Hold, with a price target of $20 from $14, after reevaluating the competitive landscape for the 2L GIST market.